VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide (2018)
Sequence: RRRRRRRRR
| Experiment Id | EXP000926 |
|---|---|
| Paper | VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide |
| Peptide | R9 (poly-arginine CPP) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | complexed with 200 pmol siRNA at N/P=8 (1 h transfection) |
| Rna Concentration | 200 pmol per well (12-well; 1 mL; 1 h exposure) |
| Mixing Ratio | N/P = 8 |
| Formulation Format | noncovalent CPP-siRNA complexes (electrostatic; N/P ratio) |
| Formulation Components | R9 peptide + siVEGF |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa and HCT116 (VEGF silencing); HeLa/HCT116/HaCat/NIH3T3 (uptake) |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro knockdown (VEGF ELISA + qRT-PCR); uptake (FACS FITC-siVEGF) |
| Output Value | HeLa: VEGF secretion down 88.1% and VEGF mRNA down 73.2% |
| Output Units | |
| Output Notes | CPP comparator; uptake by FACS with FITC-siVEGF at N/P=8. |
| Toxicity Notes | Not highlighted as toxic in these assays. |
| Curation Notes |